4.7 Article

Evidence Report: Genetic and metabolic testing on children with global developmental delay Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

期刊

NEUROLOGY
卷 77, 期 17, 页码 1629-1635

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182345896

关键词

-

资金

  1. American Academy of Neurology
  2. Child Neurology Society
  3. Pfizer Inc
  4. NIH/NINDS
  5. March of Dimes
  6. Aicardi Syndrome Foundation
  7. Weston Havens Foundation
  8. Simons Foundation
  9. US Health Resources and Services Administration
  10. Centers for Disease Control
  11. BioMarin Pharmaceutical Inc.
  12. NIH
  13. publishing Pediatric Neurology: Principles and Practice

向作者/读者索取更多资源

Objective: To systematically review the evidence concerning the diagnostic yield of genetic and metabolic evaluation of children with global developmental delay or intellectual disability (GDD/ID). Methods: Relevant literature was reviewed, abstracted, and classified according to the 4-tiered American Academy of Neurology classification of evidence scheme. Results and Conclusions: In patients with GDD/ID, microarray testing is diagnostic on average in 7.8% (Class III), G-banded karyotyping is abnormal in at least 4% (Class II and III), and subtelomeric fluorescence in situ hybridization is positive in 3.5% (Class I, II, and III). Testing for X-linked ID genes has a yield of up to 42% in males with an appropriate family history (Class III). FMR1 testing shows full expansion in at least2% of patients with mild to moderate GDD/ID (Class II and III), and MeCP2 testing is diagnostic in 1.5% of females with moderate to severe GDD/ID (Class III). Tests for metabolic disorders have a yield of up to 5%, and tests for congenital disorders of glycosylation and cerebral creatine disorders have yields of up to 2.8% (Class III). Several genetic and metabolic screening tests have been shown to have a better than 1% diagnostic yield in selected populations of children with GDD/ ID. These values should be among the many factors considered in planning the laboratory evaluation of such children. Neurology (R) 2011;77:1629-1635

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据